Amalgamated Bank Purchases 6,911 Shares of Sotera Health (NASDAQ:SHC)

Amalgamated Bank lifted its position in shares of Sotera Health (NASDAQ:SHC) by 10.9% during the 3rd quarter, Holdings Channel reports. The firm owned 70,347 shares of the company’s stock after purchasing an additional 6,911 shares during the quarter. Amalgamated Bank’s holdings in Sotera Health were worth $1,175,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Janus Henderson Group PLC boosted its position in Sotera Health by 43.6% during the first quarter. Janus Henderson Group PLC now owns 14,892,868 shares of the company’s stock worth $178,865,000 after purchasing an additional 4,525,056 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Sotera Health by 27.0% during the 1st quarter. Vanguard Group Inc. now owns 12,145,110 shares of the company’s stock worth $145,863,000 after buying an additional 2,579,248 shares during the period. Sessa Capital IM L.P. grew its stake in Sotera Health by 7.5% in the 2nd quarter. Sessa Capital IM L.P. now owns 4,300,597 shares of the company’s stock valued at $51,048,000 after buying an additional 300,597 shares during the last quarter. Darsana Capital Partners LP bought a new position in Sotera Health in the 2nd quarter valued at about $29,074,000. Finally, Untitled Investments LP lifted its position in Sotera Health by 47.0% during the first quarter. Untitled Investments LP now owns 1,409,091 shares of the company’s stock worth $16,923,000 after acquiring an additional 450,496 shares during the last quarter. 91.03% of the stock is owned by institutional investors.

Sotera Health Trading Down 1.4 %

Shares of SHC stock opened at $15.32 on Thursday. The stock has a market cap of $4.34 billion, a P/E ratio of 61.28 and a beta of 2.08. Sotera Health has a 1 year low of $10.71 and a 1 year high of $17.44. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91. The stock has a 50 day simple moving average of $16.00 and a 200 day simple moving average of $13.83.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $285.47 million during the quarter, compared to analyst estimates of $278.64 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. Sotera Health’s revenue was up 8.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.18 earnings per share. On average, research analysts predict that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the sale, the director now directly owns 49,215,301 shares in the company, valued at $739,705,974.03. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 55.12% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

SHC has been the topic of several research reports. Barclays upped their target price on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, August 6th. Citigroup upped their price objective on Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a report on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Sotera Health presently has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.